These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 26568191

  • 21. Effect of chronic kidney disease on macrophage cholesterol efflux.
    Meier SM, Wultsch A, Hollaus M, Ammann M, Pemberger E, Liebscher F, Lambers B, Fruhwürth S, Stojakovic T, Scharnagl H, Schmidt A, Springer A, Becker J, Aufricht C, Handisurya A, Kapeller S, Röhrl C, Stangl H, Strobl W.
    Life Sci; 2015 Sep 01; 136():1-6. PubMed ID: 26135622
    [Abstract] [Full Text] [Related]

  • 22. High-density lipoprotein function recent advances.
    Ansell BJ, Watson KE, Fogelman AM, Navab M, Fonarow GC.
    J Am Coll Cardiol; 2005 Nov 15; 46(10):1792-8. PubMed ID: 16286161
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment.
    Tsimihodimos V, Dounousi E, Siamopoulos KC.
    Am J Nephrol; 2008 Nov 15; 28(6):958-73. PubMed ID: 18612199
    [Abstract] [Full Text] [Related]

  • 27. Lipid and lipoprotein metabolism in chronic kidney disease.
    Kaysen GA.
    J Ren Nutr; 2009 Jan 15; 19(1):73-7. PubMed ID: 19121776
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Possible role of high density lipoprotein in the progression of glomerulosclerosis.
    Mattana J, Chaplia L, Singhal PC, Wagner JD, Valderrama E.
    J Med; 2003 Jan 15; 34(1-6):81-6. PubMed ID: 17682314
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol-regulatory enzymes and receptors in nephrotic syndrome.
    Vaziri ND, Liang K.
    Am J Nephrol; 2004 Jan 15; 24(6):606-13. PubMed ID: 15583480
    [Abstract] [Full Text] [Related]

  • 33. High-density lipoproteins, inflammation and oxidative stress.
    Tabet F, Rye KA.
    Clin Sci (Lond); 2009 Jan 15; 116(2):87-98. PubMed ID: 19076062
    [Abstract] [Full Text] [Related]

  • 34. Shift of high-density lipoprotein size distribution toward large particles in patients with proteinuria.
    Soto-Miranda E, Carreón-Torres E, Lorenzo K, Bazán-Salinas B, García-Sánchez C, Franco M, Posadas-Romero C, Fragoso JM, López-Olmos V, Madero M, Rodriguez-Pérez JM, Vargas-Alarcón G, Pérez-Méndez O.
    Clin Chim Acta; 2012 Dec 24; 414():241-5. PubMed ID: 23041214
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis.
    Kontush A, Chapman MJ.
    Pharmacol Rev; 2006 Sep 24; 58(3):342-74. PubMed ID: 16968945
    [Abstract] [Full Text] [Related]

  • 38. Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials.
    Chan DT, Irish AB, Dogra GK, Watts GF.
    Atherosclerosis; 2008 Feb 24; 196(2):823-34. PubMed ID: 17343861
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.